<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438213</url>
  </required_header>
  <id_info>
    <org_study_id>2000027951</org_study_id>
    <secondary_id>MISP59625</secondary_id>
    <nct_id>NCT04438213</nct_id>
  </id_info>
  <brief_title>Ertugliflozin in Acute Heart Failure</brief_title>
  <official_title>Ertugliflozin in Acute Heart Failure: Cardio-renal and Diuretic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects on heart failure signs and symptoms of&#xD;
      the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop&#xD;
      diuretic use in acute settings and chronic oral loop diuretic therapy.&#xD;
&#xD;
      There are two general purposes for this study. The proposed study is both larger and more&#xD;
      rigorous than essentially all PK/PD studies that form the basis of current practice with loop&#xD;
      diuretics as well as all studies looking at add-on thiazide therapy (current&#xD;
      guideline-recommended adjuvant). The second is to generate a mechanistic understanding of the&#xD;
      pleotropic cardio-renal factors with chronic therapy that differentiate ertugliflozin from&#xD;
      traditional diuretics particularly in how they maintain reduced blood volume without the&#xD;
      complication of over-diuresis and volume depletion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized placebo controlled mechanistic study to understand the utility of&#xD;
      ertugliflozin in acute and post-acute hospitalized heart failure patients with or without&#xD;
      diabetes, compared to both placebo and the active control metolazone. The broad study design&#xD;
      will be designed around evaluation of change in gold standard determined body fluid spaces&#xD;
      (blood volume, extracellular fluid, total body water), administering a sodium chloride&#xD;
      challenge, and collecting the necessary biospecimens to test our hypotheses. The general&#xD;
      study design will randomize to ertugliflozin vs. placebo early during IV diuretic therapy&#xD;
      with continuation post discharge for a total therapy of 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natriuretic effect of adjuvant to loop diuretic therapy</measure>
    <time_frame>1 day</time_frame>
    <description>The natriuretic effect (urine sodium concentration) of each arm with loop diuretic therapy will be measured by the urine sodium output.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to day 7 of total body water by add-on to loop diuretic therapy (Chronic)</measure>
    <time_frame>7 days</time_frame>
    <description>The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in total body water from baseline to day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to 6 weeks total body water by add-on to loop diuretic therapy (Chronic)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in total body water from baseline to 6 weeks.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metolazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
    <arm_group_label>Ertugliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metolazone</intervention_name>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
    <arm_group_label>Metolazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A clinical diagnosis of ADHF with at least one objective sign of volume overload&#xD;
             (rales, edema, elevated JVP, or preadmission weight gain)&#xD;
&#xD;
          2. As judged by the treating physician, a projected need and ability to tolerate&#xD;
             treatment with an extended need for IV diuretics with the goal of significant fluid&#xD;
             removal (i.e., goal &gt;1L/day net fluid loss)&#xD;
&#xD;
          3. Chronic daily oral loop diuretic dose &gt; or equal to 20mg furosemide equivalents for at&#xD;
             least one month prior to admission&#xD;
&#xD;
          4. eGFR 30 mL/min/1.73 m2&#xD;
&#xD;
          5. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current use or plan to initiate renal replacement therapy or ultrafiltration this&#xD;
             hospital admission&#xD;
&#xD;
          2. Significant bladder dysfunction or urinary incontinence&#xD;
&#xD;
          3. Inability to comply with the serial urine collection procedures&#xD;
&#xD;
          4. Current use of a thiazide or thiazide like diuretics or use within 5 half-lives of the&#xD;
             drug, including metolazone&#xD;
&#xD;
          5. Prior heart transplant, critical stenotic valvular disease or complex congenital heart&#xD;
&#xD;
          6. History of type 1 diabetes, diabetic ketoacidosis, &quot;brittle&quot; diabetes or frequent&#xD;
             hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit&#xD;
             or EMS response, glucagon administration or forced oral carbs) in the last 3 months&#xD;
&#xD;
          7. History of or current urosepsis or frequent urinary tract infections&#xD;
&#xD;
          8. Anemia with hemoglobin &lt;8g/dL (due to required phlebotomy for the study)&#xD;
&#xD;
          9. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Tainsh, RN</last_name>
    <phone>203-737-3571</phone>
    <email>jennifer.tainsh@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Testani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ertugliflozin</keyword>
  <keyword>Metolazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertugliflozin</mesh_term>
    <mesh_term>Metolazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

